Impact of 18-Fluorodeoxyglucose Positron Emission Tomography on the Management of Pancreatic Cancer

Izuishi, Kunihiko; Yamamoto, Yuka; Sano, Takanori; Takebayashi, Ryusuke; Masaki, Tsutomu; Suzuki, Yasuyuki

doi:10.1007/s11605-010-1207-x

Cited by 49 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The significant relation between tumor size and SUV has been reported by many studies and in various organs, such as colon, 16,22 pancreas, 23 and breast. 24,25 On the other hand, in our study, SUV did not correlate with tumor growth as assessed by PCNA expression.…”

Section: Discussionmentioning

confidence: 80%

Molecular Mechanism Underlying the Detection of Colorectal Cancer by 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography

Izuishi

Yamamoto

Sano

et al. 2012

Journal of Gastrointestinal Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 80%

Molecular Mechanism Underlying the Detection of Colorectal Cancer by 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography

Izuishi

Yamamoto

Sano

et al. 2012

Journal of Gastrointestinal Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

“…It was also recently reported that pancreases with PanIN can be imaged using standard FDG uptake in a mouse model 38. Several difficulties with applying FDG in clinical pancreatic cancer imaging have been identified39 and will probably limit the usefulness of this approach. In addition, while it was reported that urokinase plasminogen activator receptor could be used for targeting PDAC, amino-terminal fragment composed of 135 amino acid residue was needed to achieve efficient binding 40.…”

Section: Discussionmentioning

confidence: 99%

Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models

Cruz‐Monserrate

Abd-Elgaliel

Grote

et al. 2011

Gut

View full text Add to dashboard Cite

Background and Aims Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the USA. Surgical resection is the only effective treatment; however, only 20% of patients are candidates for surgery. The ability to detect early PDAC would increase the availability of surgery and improve patient survival. This study assessed the feasibility of using the enzymatic activity of cathepsin E (Cath E), a protease highly and specifically expressed in PDAC, as a novel biomarker for the detection of pancreas-bearing pancreatic intraepithelial neoplasia (PanIN) lesions and PDAC. Methods Pancreas from normal, chronic pancreatitis and PDAC patients was assessed for Cath E expression by quantitative real-time PCR and immunohistochemistry. Human PDAC xenografts and genetically engineered mouse models (GEMM) of PDAC were injected with a Cath E activity selective fluorescent probe and imaged using an optical imaging system. Results The specificity of Cath E expression in PDAC patients and GEMM of pancreatic cancer was confirmed by quantitative real-time PCR and immunohistochemistry. The novel probe for Cath E activity specifically detected PDAC in both human xenografts and GEMM in vivo. The Cath E sensitive probe was also able to detect pancreas with PanIN lesions in GEMM before tumour formation. Conclusions The elevated Cath E expression in PanIN and pancreatic tumours allowed in-vivo detection of human PDAC xenografts and imaging of pancreas with PanIN and PDAC tumours in GEMM. Our results support the usefulness of Cath E activity as a potential molecular target for PDAC and early detection imaging.

show abstract

“…FDG-PET has the strength of a high specificity but a striking lack of sensitivity is reported regarding small liver metastases [35]. Therefore, FDG-PET is currently not the method of choice for resectability assessment of pancreatic cancer [13,36].…”

Section: Livermentioning

confidence: 99%

Radiologic Resectability Assessment in Pancreatic Cancer

Denecke

Grieser

Bahra

2013

Fortschr Röntgenstr

View full text Add to dashboard Cite

Complete tumor resection is still the only potentially curative therapy option for patients with ductal adenocarcinoma of the pancreas. Surgical exploration is the gold standard for the determination of tumor resectability. Radiological resectability assessment is of great importance because many clearly unresectable cases can be identified preoperatively and it became essential for surgical planning. The evolving surgical and radiological techniques demand a continuous reappraisal of radiological criteria in resectability assessment. In the following, the criteria for resection planning are described along with surgical management and the role of radiology in some innovative surgical concepts is explained. Citation Format:

show abstract

Impact of 18-Fluorodeoxyglucose Positron Emission Tomography on the Management of Pancreatic Cancer

Abstract: FDG-PET is not a suitable imaging modality for either diagnosis or preoperative treatment in pancreatic cancer patients. Since it is expensive, FDG-PET as a routine diagnostic tool in pancreatic cancer patients must be used with caution.

Cited by 49 publications

References 20 publications

Molecular Mechanism Underlying the Detection of Colorectal Cancer by 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography

Molecular Mechanism Underlying the Detection of Colorectal Cancer by 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography

Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models

Radiologic Resectability Assessment in Pancreatic Cancer

Contact Info

Product

Resources

About